MedTrace Logo

cDNA and Residual Disease After Chemoradiotherapy for Locally Advanced Head and Neck Squamous Cell Carcinomas

NCT07178847 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 59

Last updated 2025-12-01

No results posted yet for this study

Summary

The goal of this ancillary clinical trial is to evaluated circulating DNA as a biomarker of residual disease after chemoradiotherapy for locally advanced head and neck squamous cell carninoma.

The main question it aims to answer is :

\- Does circulating DNA (cDNA) be able to detect residual disease 3 months after the end of chemoradiotherapy ? Researchers will compare detection of cDNA at 3-months and objective response (clinical and radiological).

Participants will :

* be included in the main study (Neck-TAR)
* have a blood sample 1 and 3-month after the end of treatment

Conditions

  • Locally Advanced Head and Neck Carcinoma

Interventions

BIOLOGICAL

blood sampling

The intervention consist in blood samples (18mL) collected 1 and 3-months after the end of chemoradiotherapy

Sponsors & Collaborators

  • Centre Jean Perrin

    lead OTHER

Principal Investigators

  • Maureen BERNADACH Coordinator, MD · Centre Jean Perrin

Study Design

Allocation
NA
Purpose
SCREENING
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-10-13
Primary Completion
2029-04-30
Completion
2031-07-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07178847 on ClinicalTrials.gov